# To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

> **NCT04550949** · PHASE3 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 700 (estimated)

## Conditions studied

- Bone Metastases

## Interventions

- **DRUG:** QL1206
- **DRUG:** Xgeva

## Key facts

- **NCT ID:** NCT04550949
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-26
- **Primary completion:** 2021-03-01
- **Final completion:** 2022-06-10
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2020-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04550949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04550949, "To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04550949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*